Against a backdrop of industry fragmentation, the company will significantly benefit from GHO’s resources, expertise and global reach in building its European practice and driving geographic expansion via M&A.ĬlearView is set to continue driving significant organic growth, cross selling emerging solutions including data analytics and pricing & market access to expand an existing client base while leveraging relationships to broaden capabilities across the small and mid-cap life sciences. Led by its founders, Rich Mynahan, Steve Chao and Kevin Richard, alongside a world-class leadership team, ClearView is well positioned to enhance its market-leading position within life sciences consulting, an industry exhibiting accelerating secular growth. ClearView services a wide range of market leading innovators across the Big Pharma/Biopharma, Diagnostics, MedTech, and life science services/tools segments.
ClearView supports drug sponsors throughout the development and commercialisation process as well as guides overall approaches to clinical and commercial portfolio development. Headquartered in Boston and with offices in New York, San Francisco, London and Zurich, ClearView is known for combining its deep and diversified therapeutic expertise with business insights to deliver actionable recommendations to its customers in support of growth and innovation strategy.
LONDON & BOSTON-( BUSINESS WIRE)-Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in global healthcare, and the founding partners of ClearView Healthcare Partners, announce a majority recapitalization of ClearView Healthcare Partners (“ClearView”), the leading life sciences strategic consultancy supporting Pharma and Biotech sponsors globally.
0 kommentar(er)
